---
document_datetime: 2025-12-08 16:21:36
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/caprelsa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: caprelsa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2590668
conversion_datetime: 2025-12-25 03:48:40.707726
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Caprelsa

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary           |                          |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------|--------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 13/11/2025                          |                                             | SmPC and PL                      | SmPC new text 4.6 | Fertility, pregnancy and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000282298                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.6 and 5.3 of the SmPC in order to update information regarding fertility and contraception based on published nonclinical data. The Package Leaflet is updated accordingly.                                                                                                                                                                  |            |             | lactation Women of childbearing potential / Contraception in males & females Women of childbearing potential and fertile men must use effective contraception during therapy and for at least four months following the last dose Fertility There are no data on the effect of vandetanib on human fertility. Results from animal studies indicate that vandetanib can impair male and female fertility (see section 5.3). 5.3 Preclinical safety data Reproductive toxicology In a fertility study of male rats, no effect on copulation or fertility rate were observed when untreated females were mated with males treated with vandetanib; however, in the same study there was a slight decrease in the number of live embryos and an increase in preimplantation loss.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000246118 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on 'Osteonecrosis' and to add it to the list of adverse drug reactions (ADRs) with frequency not known, based on a safety evaluation report. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor | 22/05/2025 | SmPC and PL | SmPC new text 4.4 Special warnings and precautions for use Osteonecrosis Events of osteonecrosis have been observed with vandetanib. An oral examination should be performed prior to initiation of vandetanib and periodically during vandetanib therapy. Patients should be advised regarding oral hygiene practice. Vandetanib treatment should be held at least 1 month prior to scheduled dental surgery or invasive dental procedures, if possible. Caution should be used in patients receiving agents associated with osteonecrosis, such as bisphosphonates. Vandetanib should be discontinued in patients who experience osteonecrosis (see section 4.8). 4.8Undesirable effects Musculoskeletal and connective tissue                                                |

<div style=\"page-break-after: always\"></div>

|                                  | changes to the PI.                                                                                                                |            |    | disorders: Osteonecrosis (Frequency Not Known) Osteonecrosis of the jaw (Frequency Not Known)   |
|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|------------|----|-------------------------------------------------------------------------------------------------|
| Article 61(3) / EMA/N/0000224361 | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives. | 06/09/2024 | PL |                                                                                                 |